Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19

NCT04435028 is registered in ClinicalTrials.gov with Horus University as lead sponsor.

NCT NCT04435028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04435028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19
Lead sponsor
Horus University
Phase
Observational
Overall status
Completed
Start date
January 14, 2019
Completion date
August 13, 2019
Enrollment
111 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, iron chelation